Results 21 to 30 of about 43,753 (252)
ARH Family of ADP-Ribose-Acceptor Hydrolases
Cells, 2022 The ARH family of ADP-ribose-acceptor hydrolases consists of three 39-kDa members (ARH1-3), with similarities in amino acid sequence. ARH1 was identified based on its ability to cleave ADP-ribosyl-arginine synthesized by cholera toxin.
Hiroko Ishiwata-Endo +6 more
doaj +1 more source
Human PARP1 substrates and regulators of its catalytic activity: An updated overview
Frontiers in Pharmacology, 2023 Poly (ADP-ribose) polymerase 1 (PARP1) is a key DNA damage sensor that is recruited to damaged sites after DNA strand breaks to initiate DNA repair. This is achieved by catalyzing attachment of ADP-ribose moieties, which are donated from NAD+, on the ...
Tao Zhu +5 more
doaj +1 more source
Poly(ADP-Ribose) Links the DNA Damage Response and Biomineralization
Cell Reports, 2019 Summary: Biomineralization of the extracellular matrix is an essential, regulated process. Inappropriate mineralization of bone and the vasculature has devastating effects on patient health, yet an integrated understanding of the chemical and cell ...
Karin H. Müller +26 more
doaj +1 more source
Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
Genome Medicine, 2018 Editorial summary Inhibitors of poly(ADP-ribose) polymerase (PARPi) have entered the clinic for the treatment of patients with cancers that lack homology-directed DNA repair, but drug resistance remains a clinical hurdle.
Paola Francica, Sven Rottenberg
doaj +1 more source
Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress
Redox Biology, 2014 Oxidative stress can cause DNA breaks which induce activation of the DNA nick sensor enzyme poly(ADP-ribose) polymerase-1 (PARP-1), part of the 17 member PARP enzyme family.
Csaba Hegedűs, László Virág
doaj +1 more source
Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma [PDF]
Current Opinion in Oncology, 2014 In 2012, two publications revealed a particular sensitivity of Ewing sarcoma cells to the inhibition of poly(ADP-ribose) polymerase (PARP). This review updates the reader on PARP function, the development of PARP inhibitors (PARPi) and the evidence for targeting PARP in Ewing sarcoma.
Vormoor, Britta, Curtin, Nicola J.
openaire +2 more sources
Inhibition of efflux transporters by poly ADP‐ribose polymerase inhibitors
Basic & Clinical Pharmacology & Toxicology, 2023 AbstractPoly ADP‐ribose polymerase (PARP) inhibitors have been approved for the treatment of various cancers. They share a similar mechanism of action but have differences in pharmacokinetic characteristics and potential for drug–drug interactions (DDI).
Feng Deng +3 more
openaire +3 more sources
Pan-cancer landscape of homologous recombination deficiency
Nature Communications, 2020 Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest ...
Luan Nguyen +3 more
doaj +1 more source
Molecules, 2023 Poly(ADP-ribose) polymerase-1 (PARP1) is a potential biomarker and therapeutic target for cancers that can catalyze the poly-ADP-ribosylation of nicotinamide adenine dinucleotide (NAD+) onto the acceptor proteins to form long poly(ADP-ribose) (PAR ...
Fengli Gao +3 more
doaj +1 more source
Neural Regeneration ResearchInherited retinal degeneration refers to untreatable blinding diseases characterized by progressive photoreceptor loss. Photoreceptor degeneration is often associated with an excessive activation of poly(ADP-ribose) polymerase and Ca2+-dependent calpain ...
Jie Yan +9 more
doaj +1 more source